T B Bevers

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint The results of a breast cancer screening cAMP at a district level in rural India
    Neha Reddy
    Northwestern University, Evanston, IL, U S A E Mail
    Asian Pac J Cancer Prev 13:6067-72. 2012
  2. ncbi request reprint The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women
    Therese B Bevers
    The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1322, Houston, TX 77030, USA
    J Natl Compr Canc Netw 5:719-24. 2007
  3. ncbi request reprint Raloxifene and the prevention of breast cancer
    Therese B Bevers
    Cancer Prevention Center, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Expert Opin Pharmacother 7:2301-7. 2006
  4. ncbi request reprint Breast cancer chemoprevention: current clinical practice and future direction
    T B Bevers
    The University of Texas M D Anderson Cancer Center Clinical Cancer Prevention, Houston 77030, USA
    Biomed Pharmacother 55:559-64. 2001
  5. ncbi request reprint Quality of life and sexual functioning in cervical cancer survivors
    Michael Frumovitz
    Department of Gynecologic Oncology, 1155 Herman Pressler, CPB6 3244, Unit 1362, Houston, TX 77030, USA
    J Clin Oncol 23:7428-36. 2005
  6. ncbi request reprint Phase II clinical trial of N-(4-Hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia
    S Eva Singletary
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 8:2835-42. 2002
  7. ncbi request reprint Are there racial differences in breast cancer treatments and clinical outcomes for women treated at M.D. Anderson Cancer Center?
    Yu Shen
    Department of Biostatistics and Applied Mathematics, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 447, Houston, TX 77030, USA
    Breast Cancer Res Treat 102:347-56. 2007
  8. pmc Genetic variants in the H2AFX promoter region are associated with risk of sporadic breast cancer in non-Hispanic white women aged <or=55 years
    Jiachun Lu
    Department of Epidemiology, Unit 1365, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA
    Breast Cancer Res Treat 110:357-66. 2008
  9. pmc Prognostic role of detection method and its relationship with tumor biomarkers in breast cancer: the university of Texas M.D. Anderson Cancer Center experience
    Wenli Dong
    Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Epidemiol Biomarkers Prev 17:1096-103. 2008
  10. ncbi request reprint Breast cancer screening and diagnosis
    Therese B Bevers
    University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    J Natl Compr Canc Netw 4:480-508. 2006

Detail Information

Publications13

  1. ncbi request reprint The results of a breast cancer screening cAMP at a district level in rural India
    Neha Reddy
    Northwestern University, Evanston, IL, U S A E Mail
    Asian Pac J Cancer Prev 13:6067-72. 2012
    ..Further studies are needed in countries like India to identify the best screening tool to decrease the presentation of breast cancer in advanced stages and to reduce mortality...
  2. ncbi request reprint The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women
    Therese B Bevers
    The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1322, Houston, TX 77030, USA
    J Natl Compr Canc Netw 5:719-24. 2007
    ..Since the unblinding of the STAR trial in 2006, raloxifene has emerged as an option for reducing breast cancer risk for postmenopausal women at increased risk for the disease...
  3. ncbi request reprint Raloxifene and the prevention of breast cancer
    Therese B Bevers
    Cancer Prevention Center, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Expert Opin Pharmacother 7:2301-7. 2006
    ..When raloxifene becomes FDA approved for breast cancer risk reduction, postmenopausal women will have a second option to reduce their risk...
  4. ncbi request reprint Breast cancer chemoprevention: current clinical practice and future direction
    T B Bevers
    The University of Texas M D Anderson Cancer Center Clinical Cancer Prevention, Houston 77030, USA
    Biomed Pharmacother 55:559-64. 2001
    ..Findings are anticipated in 2006...
  5. ncbi request reprint Quality of life and sexual functioning in cervical cancer survivors
    Michael Frumovitz
    Department of Gynecologic Oncology, 1155 Herman Pressler, CPB6 3244, Unit 1362, Houston, TX 77030, USA
    J Clin Oncol 23:7428-36. 2005
    ..To compare quality of life and sexual functioning in cervical cancer survivors treated with either radical hysterectomy and lymph node dissection or radiotherapy...
  6. ncbi request reprint Phase II clinical trial of N-(4-Hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia
    S Eva Singletary
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 8:2835-42. 2002
    ..Surrogate end point biomarkers (SEBs) that can be measured in ductal carcinoma in situ or early-stage invasive cancer are needed to improve the efficiency and reduce the cost of chemoprevention trials...
  7. ncbi request reprint Are there racial differences in breast cancer treatments and clinical outcomes for women treated at M.D. Anderson Cancer Center?
    Yu Shen
    Department of Biostatistics and Applied Mathematics, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 447, Houston, TX 77030, USA
    Breast Cancer Res Treat 102:347-56. 2007
    ..To determine the influence of race on breast cancer treatment and on recurrence and breast cancer specific death...
  8. pmc Genetic variants in the H2AFX promoter region are associated with risk of sporadic breast cancer in non-Hispanic white women aged <or=55 years
    Jiachun Lu
    Department of Epidemiology, Unit 1365, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA
    Breast Cancer Res Treat 110:357-66. 2008
    ..Larger association studies and related functional studies are warranted to confirm these findings...
  9. pmc Prognostic role of detection method and its relationship with tumor biomarkers in breast cancer: the university of Texas M.D. Anderson Cancer Center experience
    Wenli Dong
    Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Epidemiol Biomarkers Prev 17:1096-103. 2008
    ..To assess the effect of tumor detection method (screening versus symptom-based diagnosis) in predicting breast cancer survival and investigate how biological features of breast cancer are related to the tumor detection method...
  10. ncbi request reprint Breast cancer screening and diagnosis
    Therese B Bevers
    University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    J Natl Compr Canc Netw 4:480-508. 2006
  11. ncbi request reprint Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial
    Victor G Vogel
    Magee Womens Hospital, University of Pittsburgh School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213 3221, USA
    JAMA 295:2727-41. 2006
    ..Tamoxifen is approved for the reduction of breast cancer risk, and raloxifene has demonstrated a reduced risk of breast cancer in trials of older women with osteoporosis...
  12. ncbi request reprint Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study
    Bernard Fisher
    Operations Center, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
    J Natl Cancer Inst 97:1652-62. 2005
    ..Side effects of varying clinical significance were observed. The trial was unblinded because of the positive results, and follow-up continued. This report updates our initial findings...
  13. ncbi request reprint Breast cancer risk reduction
    Therese B Bevers
    National Comprehensive Cancer Network
    J Natl Compr Canc Netw 5:676-701. 2007